1. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma
   N. Kramkimel et al, 2016, Targeted Oncology CrossRef
2. Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival
   Go Woon Kim et al, 2015, Lung Cancer CrossRef
3. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status
   Dalong Wang et al, 2016, PLOS ONE CrossRef
4. Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer
   Lonneke Timmers et al, 2015, Journal of Cancer Research and Clinical Oncology CrossRef